Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution
出版年份 2020 全文链接
标题
Status of 10 targeted genes of non‐small cell lung cancer in eastern China: A study of 884 patients based on
NGS
in a single institution
作者
关键词
-
出版物
Thoracic Cancer
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-07-30
DOI
10.1111/1759-7714.13577
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line
- (2020) Yoshinori Tsukumo et al. PLoS One
- Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China
- (2020) Fei Xu et al. Thoracic Cancer
- Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis
- (2019) Ruiying Zhao et al. Molecular Diagnosis & Therapy
- Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
- (2019) Badi El Osta et al. Journal of Thoracic Oncology
- Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer
- (2019) Chen Lin et al. LUNG CANCER
- Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR , ALK , ROS1 , KRAS or BRAF
- (2019) Xibin Zhuang et al. Cancer Medicine
- The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients
- (2019) Quan Lin et al. Journal of Translational Medicine
- Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
- (2019) Xuejuan Gao et al. Cancer Management and Research
- Epidermal growth factor receptor first generation tyrosine-kinase inhibitors
- (2019) Alex Martinez-Marti et al. Translational Lung Cancer Research
- Worldwide Frequency of Commonly Detected EGFR Mutations
- (2018) Rondell P. Graham et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Primary and acquired EGFR T790M-mutant NSCLC patients identified by routine mutation testing show different characteristics but may both respond to osimertinib treatment
- (2018) Weihua Li et al. CANCER LETTERS
- Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer
- (2018) Karen L. Reckamp Journal of the National Comprehensive Cancer Network
- GOPC - ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma
- (2018) Liang Zeng et al. Journal of Thoracic Oncology
- Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma
- (2018) Mengnan Zhao et al. Journal of Thoracic Disease
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation
- (2018) Shuyuan Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Hmwe Hmwe Kyu et al. LANCET
- Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
- (2017) Sabine Schmid et al. Journal of Thoracic Oncology
- Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib
- (2017) Sai-Hong Ignatius Ou et al. LUNG CANCER
- Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma
- (2017) Zhenya Tang et al. MODERN PATHOLOGY
- Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy
- (2017) Motonobu Saito et al. SURGERY TODAY
- Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer
- (2017) Wentao Hu et al. Oncotarget
- Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer
- (2017) Jianping Xu et al. Cancer Biomarkers
- Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer
- (2016) Shi Bu et al. ANNALS OF SURGICAL ONCOLOGY
- Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
- (2016) Xuefei Li et al. BMC CANCER
- Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion–Positive Metastatic Non–Small-Cell Lung Cancer
- (2016) Gerald S. Falchook et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma
- (2016) Shiyong Li et al. Journal of Thoracic Oncology
- ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare
- (2016) Weijie Zhao et al. LUNG CANCER
- The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis
- (2015) Chen Lin et al. CANCER BIOLOGY & THERAPY
- Genomic alterations in lung adenocarcinoma
- (2015) Siddhartha Devarakonda et al. LANCET ONCOLOGY
- Present and Future Molecular Testing of Lung Carcinoma
- (2014) Sanja Dacic et al. ADVANCES IN ANATOMIC PATHOLOGY
- Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts
- (2014) S Li et al. BRITISH JOURNAL OF CANCER
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
- (2013) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor
- (2013) Eamon M. Berge et al. SEMINARS IN ONCOLOGY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
- (2012) Ken Takezawa et al. Cancer Discovery
- Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains
- (2011) Chenguang Li et al. Journal of Thoracic Oncology
- EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
- (2009) Tae Won Jang et al. KOREAN JOURNAL OF INTERNAL MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More